Overview

My focus is in the treatment and long term outcomes of children treated for cancer. My specific focus is in quantifying what complications are seen in survivors of childhood cancer. Specifically, I am interested in trying to identify genetic markers that may identify those who are at risk of a specific complication. We are currently in the process of identifying genes that may explain why 20-50% of children receiving cisplatin have irreversible hearing loss. We have established a database of all adverse events in children treated through the oncology department at BC Children's Hospital. I am also interested in using linked databases to look at hospital utilization in long term survivors. Finally, I am interested in developing clinical trials in pediatric oncology both locally, as well as through the Children's Oncology Group (COG).

Publications

Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research.
Clinical pharmacology and therapeutics
Drögemöller BI and Wright GEB and Lo C and Le T and Brooks B and Bhavsar AP and Rassekh SR and Ross CJD and Carleton BC
DOI: 10.1002/cpt.1483
PubMed: 31012503
06/2019

ALK-Positive Lung Adenocarcinoma Arising in an Adolescent Treated for Relapsed Neuroblastoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Alwelaie Y and Deyell RJ and Nadel HR and Tucker T and Laskin J and Rassekh SR and Zhou C and English JC and Lee AF
DOI: 10.1016/j.jtho.2019.02.010
PubMed: 31122568
06/2019

Pediatric oncology and stem cell transplant patients with healthcare-associated Clostridium difficile infection were already colonized on admission.
Pediatric blood & cancer
Al-Rawahi GN and Al-Najjar A and McDonald R and Deyell RJ and Golding GR and Brant R and Tilley P and Thomas E and Rassekh SR and O'Gorman A and Wong P and Turnham L and Dobson S
DOI: 10.1002/pbc.27604
PubMed: 30666782
01/2019

Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218
Pediatric Blood and Cancer
DOI: 10.1002/pbc.27540
2019

Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes
Clinical Pharmacology and Therapeutics
DOI: 10.1002/cpt.1179
2019

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines
Breast Cancer Research and Treatment
DOI: 10.1007/s10549-018-5027-0
2019

Tri-ponderal mass index in survivors of childhood brain tumors: A cross-sectional study.
Scientific reports
Sims ED and Wang KW and Fleming A and Johnston DL and Zelcer SM and Rassekh SR and Burrow S and Thabane L and Samaan MC
DOI: 10.1038/s41598-018-34602-5
PubMed: 30397217
11/2018

Clinical significance in pediatric oncology randomized controlled treatment trials: a systematic review.
Trials
Howard AF and Goddard K and Rassekh SR and Samargandi OA and Hasan H
DOI: 10.1186/s13063-018-2925-8
PubMed: 30290839
10/2018

Tumor Variant Identification That Accounts for the Unique Molecular Landscape of Pediatric Malignancies.
JNCI cancer spectrum
Lorentzian A and Biegel JA and Ostrow DG and Rolf N and Liu CC and Rassekh SR and Deyell RJ and Triche T and Schultz KR and Rozmus J and Reid GSD and Lim CJ and Lange PF and Maxwell CA
DOI: 10.1093/jncics/pky079
PubMed: 30976750
10/2018

High incidence of acute kidney injury during chemotherapy for childhood acute myeloid leukemia
Pediatric Blood & Cancer
Liezl Du Plessis and Shahrad Rod Rassekh and Cherry Mammen
DOI: 10.1002/pbc.26915
04/2018

Comparative RNA-Sequencing Analysis Benefits a Pediatric Patient With Relapsed Cancer.
JCO precision oncology
Newton Y and Rassekh SR and Deyell RJ and Shen Y and Jones MR and Dunham C and Yip S and Leelakumari S and Zhu J and McColl D and Swatloski T and Salama SR and Ng T and Hendson G and Lee AF and Morozova O
04/2018

Comparative RNA-Sequencing Analysis Benefits a Pediatric Patient With Relapsed Cancer.
JCO precision oncology
Newton Y and Rassekh SR and Deyell RJ and Shen Y and Jones MR and Dunham C and Yip S and Leelakumari S and Zhu J and McColl D and Swatloski T and Salama SR and Ng T and Hendson G and Lee AF and Morozova O
DOI: 10.1200/po.17.00198
PubMed: 31372595
04/2018

Reply to: Comment on: Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review
Pediatric Blood & Cancer
Haroon Hasan and Omar Mohammad Shaikh and Shahrad Rod Rassekh and A. Fuchsia Howard and Karen Goddard
DOI: 10.1002/pbc.27106
04/2018

Application of genomics to identify therapeutic targets in recurrent pediatric papillary thyroid carcinoma
Molecular Case Studies
Rebecca Ronsley and S. Rod Rassekh and Yaoqing Shen and Anna F. Lee and Colleen Jantzen and Jessica Halparin and Catherine Albert and Douglas S. Hawkins and Shazhan Amed and Ralph Rothstein and Andrew J. Mungall and David Dix and Geoffrey Blair and Helen Nadel and Steven J.M. Jones and Janessa Laskin and Marco A. Marra and Rebecca J. Deyell
DOI: 10.1101/mcs.a002568
04/2018

Birth weight and body mass index z-score in childhood brain tumors: A cross-sectional study
Scientific Reports
Kuan-Wen Wang and Russell J. de Souza and Adam Fleming and Donna L. Johnston and Shayna M. Zelcer and Shahrad Rod Rassekh and Sarah Burrow and Lehana Thabane and M. Constantine Samaan
DOI: 10.1038/s41598-018-19924-8
01/2018

Overweight, obesity and adiposity in survivors of childhood brain tumours: a systematic review and meta-analysis
Clinical obesity
DOI: 10.1111/cob.12224
2018

An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines
Pediatric Blood and Cancer
DOI: 10.1002/pbc.26887
2018

Adiposity in childhood brain tumors: A report from the Canadian Study of Determinants of Endometabolic Health in Children (CanDECIDE Study).
Scientific reports
Wang KW and Souza RJ and Fleming A and Singh SK and Johnston DL and Zelcer SM and Rassekh SR and Burrow S and Scheinemann K and Thabane L and Samaan MC
DOI: 10.1038/srep45078
PubMed: 28327649
03/2017

Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort Study.
Canadian Journal of Kidney Health and Disease
McMahon KR and Rod Rassekh S and Schultz KR and Pinsk M and Blydt-Hansen T and Mammen C and Tsuyuki RT and Devarajan P and Cuvelier GD and Mitchell LG and Baruchel S and Palijan A and Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Group
DOI: 10.1177/2054358117690338
PubMed: 28270931
02/2017

Acute Kidney Injury During Chemotherapy for Acute Myeloid Leukemia
Pediatric Blood & Cancer
2017

Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer
British Journal of Clinical Pharmacology
DOI: 10.1111/bcp.13218
2017

Long-term Outcomes and Complications in Pediatric Ewing Sarcoma
American Journal of Clinical Oncology: Cancer Clinical Trials
DOI: 10.1097/COC.0000000000000176
2017

Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits
Scientific Reports
DOI: 10.1038/s41598-017-10269-2
2017

The effectiveness of interventions to treat hypothalamic obesity in survivors of childhood brain tumours: a systematic review
Obesity Reviews
DOI: 10.1111/obr.12534
2017

Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review
Pediatric Blood and Cancer
DOI: 10.1002/pbc.26200
2017

Management of germline findings revealed throughout the course of tumor-normal whole genome sequencing in oncology.
Journal of Clinical Oncology
DOI: 10.1200/JCO.2017.35.15_suppl.e13113
2017

MB-91OUTCOMES FOR YOUNG CHILDREN WITH BRAIN TUMOURS TREATED ACCORDING TO THE HEAD START PROTOCOLS: A SINGLE-CENTRE EXPERIENCE.
Neuro-oncology
Szpurko A and O'Halloran K and Potts J and Dunham C and Goddard K and Davis J and Strahlendorf C and Rassekh SR and Hukin J
DOI: 10.1093/neuonc/now076.87
05/2016

Clinical Implimentation of a Pharmacogenetic Risk Prediction Model for Cisplatin Ototoxicity and Anthracycline Cardiotoxicity
Pediatric Blood & Cancer
2016

Hypotension associated with ingestion of cannabinoids in two children with cancer
CMAJ
DOI: 10.1503/cmaj.150847
2016

ETV6-NTRK3 is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors
American Journal of Surgical Pathology
DOI: 10.1097/PAS.0000000000000677
2016

Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity
British Journal of Clinical Pharmacology
DOI: 10.1111/bcp.13008
2016

Outcome of young children with high-grade glioma treated with irradiation-avoiding intensive chemotherapy regimens: Final report of the Head Start II and III trials
Pediatric Blood and Cancer
DOI: 10.1002/pbc.26118
2016

Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers
Therapeutic Drug Monitoring
DOI: 10.1097/FTD.0000000000000298
2016

Early-onset liver failure with palpable abdominal mass in a neonate
NeoReviews
DOI: 10.1542/neo.17-10-e624
2016

When Parents Refuse Potentially Curative Treatment for their Child's Cancer - Does Legal Intervention Improve Outcome?
Pediatric Blood & Cancer
2016

Pharmacogenomic Strategies for the Prevention of Anthracycline-Induced Heart Failure: Validation of a Genetic Association with a Non-Synonymous Variant in RARG
Pediatric Blood & Cancer
2016

OUTCOMES FOR YOUNG CHILDREN WITH BRAIN TUMOURS TREATED ACCORDING TO THE HEAD START PROTOCOLS: A SINGLE-CENTRE EXPERIENCE
Neuro-Oncology
2016

Harnessing the power of big data to advance pediatric cancer care
Cancer Research
2016

Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children (vol 16, pg 1065, 2015)
Pharmacogenomics
2016

Comparison of Hypersensitivity Rates to Intravenous and Intramuscular PEG-Asparaginase in Children with Acute Lymphoblastic Leukemia: A Meta-Analysis and Systematic Review
Pediatric Blood & Cancer
2016

Evolution of a Pediatric Primary Cerebral ALK-1-Positive Anaplastic Large Cell Lymphoma on Serial MRI.
Pediatric neurosurgery
Dunbar MJ and Singhal A and Rassekh SR and Dunham C
DOI: 10.1159/000380769
PubMed: 25896198
04/2015

PEDIATRIC PERSONALIZED ONCOGENOMICS (PEDSPOG) - INITIAL OUTCOMES
Pediatric Blood & Cancer
2015

Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children
Pharmacogenomics
DOI: 10.2217/pgs.15.61
2015

Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy
Therapeutic Drug Monitoring
DOI: 10.1097/FTD.0000000000000192
2015

Cisplatin Nephrotoxicity and Longitudinal Growth in Children with Solid Tumors
Medicine (United States)
DOI: 10.1097/MD.0000000000001413
2015

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer
Nature Genetics
DOI: 10.1038/ng.3374
2015

High-dose chemotherapy/stem cell transplantation (Hdsct)
Pediatric Neuro-oncology
DOI: 10.1007/978-1-4939-1541-5
2015

Whole genome analysis in a population-based cancer system: Results from sequencing > 100 metastatic cancer patients
European Journal of Cancer
2015

Management of germline findings revealed throughout the course of tumor-normal whole genome sequencing in oncology
European Journal of Cancer
2015

Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children
Pharmacogenomics
DOI: 10.2217/PGS.15.61
2015

Characterizing standardized uptake values on diagnostic PET/CT scans according to pediatric lymphoma subtypes
Journal of Nuclear Medicine
2015

ASSESSING THE ACCURACY OF DEATH RECORDS AND PRE-MORTEM CLINICAL DIAGNOSES: A RETROSPECTIVE CHART REVIEW OF DECEASED CHILDREN DIAGNOSED WITH BRAIN TUMOURS IN BRITISH COLUMBIA, CANADA
Pediatric Blood & Cancer
2014

Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients
Pediatric Blood and Cancer
DOI: 10.1002/pbc.24847
2014

Response to "Evaluation of Pharmacogenetic Markers to Predict the Risk of Cisplatin-Induced Ototoxicity"
Clinical Pharmacology and Therapeutics
DOI: 10.1038/clpt.2014.90
2014

Genetic markers of cisplatin-induced hearing loss in children
Clinical Pharmacology and Therapeutics
DOI: 10.1038/clpt.2014.92
2014

Diagnostic value of next-generation sequencing in an unusual sphenoid tumor
Oncologist
DOI: 10.1634/theoncologist.2013-0390
2014

Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity
Clinical Pharmacology and Therapeutics
DOI: 10.1038/clpt.2013.219
2014

Growing teratoma syndrome in intracranial non-germinomatous germ cell tumors (iNGGCTs): A risk for secondary malignant transformation - A report of two cases
Child's Nervous System
DOI: 10.1007/s00381-013-2295-1
2014

Intra-arterial methylprednisolone for severe steroid refractory gastrointestinal graft-versus-host disease
Pediatric Blood and Cancer
DOI: 10.1002/pbc.25155
2014

Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent
Pharmacogenomics Journal
DOI: 10.1038/tpj.2013.13
2014

Vincristine and fine motor function of children with acute lymphoblastic leukemia
Canadian Journal of Occupational Therapy
DOI: 10.1177/0008417414539926
2014

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children
Pediatric Blood and Cancer
DOI: 10.1002/pbc.24932
2014

CHARACTERIZING STANDARDIZED UPTAKE VALUES ON DIAGNOSTIC PET/CT SCANS ACCORDING TO PEDIATRIC LYMPHOMA SUBTYPES
Pediatric Blood & Cancer
2014

GENETIC VARIANTS IN SLC22A17 AND SLC22A7 ARE ASSOCIATED WITH ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN CHILDREN
Pediatric Blood & Cancer
2014

PERSONALIZING THE TREATMENT OF PEDIATRIC MEDULLOBLASTOMA: POLO-LIKE KINASE 1 AS A MOLECULAR TARGET IN HIGH-RISK CHILDREN
Neuro-Oncology
2014

POLO-LIKE KINASE 1 (PLK1) ACTIVATES TRANSLATIONALLY CONTROLLED TUMOR PROTEIN (TCTP) PROMOTING THE DEVELOPMENT OF REFRACTORY MEDULLOBLASTOMA
Neuro-Oncology
2014

RISK AND PATTERNS OF UTILIZATION OF COMMUNITY CARE AND MENTAL HEALTH SERVICES AMONG CHILDHOOD, ADOLESCENT AND YOUNG ADULT CANCER SURVIVORS IN BRITISH COLUMBIA, CANADA
Pediatric Blood & Cancer
2014

Comparative genomic hybridization of Wilms' tumor.
Methods in molecular biology (Clifton, N.J.)
Rassekh SR and Rajcan-Separovic E
DOI: 10.1007/978-1-62703-281-0_16
PubMed: 23412795
01/2013

Antidepressant use among survivors of childhood, adolescent and young adult cancer: A report of the childhood, adolescent and young adult cancer survivor (CAYACS) research program
Pediatric Blood & Cancer
DOI: 10.1002/pbc.24446
2013

Outcome of infants and young children with newly diagnosed ependymoma treated on the "head Start" III prospective clinical trial
Journal of Neuro-Oncology
DOI: 10.1007/s11060-013-1111-9
2013

Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children
Clinical Pharmacology and Therapeutics
DOI: 10.1038/clpt.2013.80
2013

Cancer pharmacogenomics in children: Research initiatives and progress to date
Pediatric Drugs
DOI: 10.1007/s40272-013-0021-9
2013

Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children
Pediatric Blood and Cancer
DOI: 10.1002/pbc.24505
2013

Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children
Cancer Research
DOI: 10.1158/0008-5472.CAN-12-4331
2013

Erratum: Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy (Nature Genetics (2009) 41 (1345-1349))
Nature Genetics
DOI: 10.1038/ng.0513-578
2013

Prenatal presentation of fronto-orbital congenital infantile fibrosarcoma: A clinicopathologic report
JAMA Ophthalmology
DOI: 10.1001/jamaophthalmol.2013.1934
2013

Cancer Pharmacogenomics in Children
Cancer Genomics: From Bench to Personalized Medicine
DOI: 10.1016/B978-0-12-396967-5.00006-2
2013

Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy
Journal of Population Therapeutics and Clinical Pharmacology
2013

PERSONALIZING THE TREATMENT FOR MEDULLOBLASTOMA: POLO-LIKE KINASE 1 (PLK1) AS A MOLECULAR TARGET FOR THE SONIC HEDGEHOG (SHH) SUBTYPE
Neuro-Oncology
2013

Pharmacogenetics of warfarin safety and effectiveness in children
Faseb Journal
2013

Pharmacogenomics of vincristine-induced neurotoxicity in pediatric cancer patients
Faseb Journal
2013

PHARMACOGENOMICS OF VINCRISTINE-INDUCED NEUROTOXICITY IN PEDIATRIC CANCER PATIENTS
Pediatric Blood & Cancer
2013

Predicting Anthracycline-induced Cardiotoxicity in Children - Genome-Wide Association Study
Faseb Journal
2013

THE Y-BOX BINDING PROTEIN-1 CONVEYS TEMOZOLOMIDE RESISTANCE BY THE INHIBITING DNA DAMAGE RESPONSE PATHWAY THROUGH THE POLYCOMB REPRESSOR BMI-1
Neuro-Oncology
2013

Atypical Teratoid Rhabdoid Tumors (ATRTs): The British Columbia's Children's Hospital's Experience, 1986-2006
Brain Pathology
DOI: 10.1111/j.1750-3639.2011.00561.x
2012

Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children
Journal of Clinical Oncology
DOI: 10.1200/JCO.2010.34.3467
2012

Economic impact of a genetic test for cisplatin-induced ototoxicity
Pharmacogenomics Journal
DOI: 10.1038/tpj.2011.15
2012

Erratum: Economic impact of a genetic test for cisplatin-induced ototoxicity (The Pharmacogenomics Journal (2012) 12 (205-213) DOI: 10.1038/tpj.2011.15)
Pharmacogenomics Journal
DOI: 10.1038/tpj.2011.21
2012

Platinum-induced ototoxicity in children: A consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale
Journal of Clinical Oncology
DOI: 10.1200/JCO.2011.39.1110
2012

Possible differentiation of cerebral glioblastoma into pleomorphic xanthoastrocytoma: An unusual case in an infant - Case report
Journal of Neurosurgery: Pediatrics
DOI: 10.3171/2012.1.PEDS11326
2012

CHARACTERISTICS OF HIGH HEALTH CARE USERS AMONG CHILDHOOD, ADOLESCENT AND YOUNG ADULT CANCER SURVIVORS IN BRITISH COLUMBIA, CANADA
Pediatric Blood & Cancer
2012

GENETIC PREDISPOSITION TO ADVERSE EVENTS
Pediatric Blood & Cancer
2012

MALIGNANT TRANSFORMATION OF GROWING TERATOMAS: A GROWING PHENOMENON
Neuro-Oncology
2012

OUTCOMES OF CHILDREN TREATED WITH A CHEMOTHERAPY-ONLY INFANT PROTOCOL AT BRITISH COLUMBIA'S CHILDREN'S HOSPITAL
Neuro-Oncology
2012

Pharmacogenetics of Warfarin in Children
Pharmacoepidemiology and Drug Safety
2012

Pharmacogenomics of serious adverse drug reactions in pediatric oncology.
Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique
Ross CJ and Visscher H and Rassekh SR and Castro-Pastrana LI and Shereck E and Carleton B and Hayden MR
PubMed: 21467604
03/2011

FINAL REPORT ON OUTCOME OF CHILDREN WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMA (HGG) TREATED WITH MULTI-DRUG INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATIVE MYELOABLATIVE CHEMOTHERAPY AND AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL RESCUE (AuHPCR) ON THE "HEAD START" II AND III PROTOCOLS
Neuro-Oncology
2011

Severe genital ulceration in an acute epstein-barr virus infection
Pediatric Infectious Disease Journal
DOI: 10.1097/INF.0b013e3181f41b2e
2011

Nephrotic syndrome developing during induction chemotherapy for childhood acute lymphoblastic leukemia
Clinical and Experimental Nephrology
DOI: 10.1007/s10157-010-0401-1
2011

Pharmacogenomics of serious adverse drug reactions in pediatric oncology
Journal of Population Therapeutics and Clinical Pharmacology
2011

HIGH INCIDENCE OF FUNGAL INFECTIONS IN PEDIATRIC ONCOLOGY PATIENTS IN BRITISH COLUMBIA
Pediatric Blood & Cancer
2011

LATE MORBIDITY AS MEASURED BY HOSPITAL ADMISSIONS AMONG SURVIVORS OF CHILDHOOD WILMS TUMORS
Pediatric Blood & Cancer
2011

Outcome of Head Start III multinational protocol for newly diagnosed central nervous system (CNS) primitive neuroectodermal tumors (pnet) of young children.
Journal of Clinical Oncology
2011

OUTCOME OF INFANTS AND YOUNG CHILDREN WITH NEWLY DIAGNOSED EPENDYMOMA TREATED ON "HEAD START" III PROTOCOL
Neuro-Oncology
2011

Pathology, genetics and cytogenetics of Wilms' tumour
Pathology
DOI: 10.1097/PAT.0b013e3283463575
2011

Reclassification of ICD-9 Codes into Meaningful Categories for Oncology Survivorship Research.
Journal of cancer epidemiology
Rassekh SR and Lorenzi M and Lee L and Devji S and McBride M and Goddard K
DOI: 10.1155/2010/569517
PubMed: 21234317
12/2010

Abnormal Liver Transaminases and Conjugated Hyperbilirubinemia at Presentation of Acute Lymphoblastic Leukemia
Pediatric Blood & Cancer
DOI: 10.1002/pbc.22549
2010

Childhood, adolescent, and young adult cancer survivors research program of British Columbia: Objectives, study design, and cohort characteristics
Pediatric Blood and Cancer
DOI: 10.1002/pbc.22476
2010

CASE-BASED INTERACTIVE E-LEARNING PROGRAMS FOR PEDIATRIC ONCOLOGY: RATIONALE, DEVELOPMENT AND USER EVALUATION RESULTS
Pediatric Blood & Cancer
2010

HEALTH CARE PROVIDERS' VIEWS OF INFORMED CONSENT AND JOINT DECISION MAKING IN PEDIATRIC PATIENTS WITH BRAIN TUMOURS
Pediatric Blood & Cancer
2010

LACK OF CISPLATIN INDUCED HEARING LOSS AS A PREDICTOR OF A POOR OUTCOME IN CHILDREN WITH OSTEOSARCOMA
Pediatric Blood & Cancer
2010

OTOTOXICITY AS A PREDICTOR OF OUTCOME IN OSTEOSARCOMA PATIENTS TREATED WITH CISPLATIN
Journal of Investigative Medicine
2010

OTOTOXICITY AS A PREDICTOR OF OUTCOME IN PATIENTS WITH OSTEOSARCOMA TREATED WITH CISPLATIN
Pediatric Blood & Cancer
2010

PROGNOSTIC FACTORS INFLUENCING SURVIVAL FOR CNS ATYPICAL TERATOID RHABDOID TUMORS IN BRITISH COLUMBIA
Pediatric Blood & Cancer
2010

REDEFINING THE INCIDENCE AND OUTCOMES OF CNS ATYPICAL TERATOID RHABDOID TUMOURS AT BC CHILDREN'S HOSPITAL
Pediatric Blood & Cancer
2010

REDEFINING THE INCIDENCE, OUTCOMES, AND PROGNOSTIC FACTORS FOR CNS ATYPICAL TERATOID RHABDOID TUMOURS AT BC CHILDREN'S HOSPITAL
Neuro-Oncology
2010

RESECTION ALONE IN LIEU OF ADJUVANT THERAPY IN THE TREATMENT OF MEDULLOBLASTOMA IN GORLIN SYNDROME
Neuro-Oncology
2010

Inflammatory myofibroblastic tumour of the subglottis in a 5-year-old.
Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
Hartl T and Moxham JP and Ludemann JP and Rassekh SR
PubMed: 19476756
06/2009

In vitro inferiority of ceftazidime compared with other beta-lactams for viridans group Streptococcus bacteremia in pediatric oncology patients: implications for antibiotic choices.
Journal of pediatric hematology/oncology
Paulus S and Dobson S and Rassekh S and Blondel-Hill E
DOI: 10.1097/mph.0b013e31819a5d40
PubMed: 19346878
04/2009

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy
Nature Genetics
DOI: 10.1038/ng.478
2009

Inflammatory myofibroblastic tumour of the subglottis in a 5-year-old
Journal of Otolaryngology - Head and Neck Surgery
DOI: 10.2310/7070.2009.080211
2009

In vitro inferiority of ceftazidime compared with other ß-lactams for viridans group streptococcus bacteremia in pediatric oncology patients: Implications for antibiotic choices
Journal of Pediatric Hematology/Oncology
DOI: 10.1097/MPH.0b013e31819a5d40
2009

IDENTIFICATION OF GENETIC MARKERS OF SEVERE HEARING LOSS IN CHILDREN RECEIVING CISPLATIN
Pediatric Blood & Cancer
2009

In Vitro Inferiority of Ceftazidime Compared With Other beta-lactams for Viridans Group Streptococcus Bacteremia in Pediatric Oncology Patients Implications for Antibiotic Choices
Journal of Pediatric Hematology Oncology
2009

Late hospitalizations among survivors of pediatric brain tumors
Neuro-Oncology
2008

Screening for submicroscopic chromosomal rearrangements in Wilms tumor using whole-genome microarrays
Cancer Genetics and Cytogenetics
DOI: 10.1016/j.cancergencyto.2007.12.015
2008

Canadian national active surveillance network for adverse drug reactions: Genotypic approaches to therapy in children (GATC): The first year
Pharmacoepidemiology and Drug Safety
2007

Genotypic approaches to therapy in children: A national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children
Annals of the New York Academy of Sciences
DOI: 10.1196/annals.1423.020
2007

A roadmap for engaging first nations communities in medical research.
Journal of Investigative Medicine
2004

Adults with myelomeningocele: Functional outcome of the last 5 years of graduates from a children's hospital
Journal of Investigative Medicine
2003

Promoting healthy food choices among children in first nations communities.
Journal of Investigative Medicine
2003

Validity and reliability of a pediatric pneumonia score
Journal of Investigative Medicine
2003

Functional deterioration following placode untethering in myelomeningocele.
Pediatric neurosurgery
Cochrane DD and Rassekh SR and Thiessen PN
DOI: 10.1159/000028621
PubMed: 9693332
02/1998

Functional deterioration following placode untethering in myelomeningocele
Pediatric Neurosurgery
1998

Research

Genotype-Specific Approaches to Therapy in Children with Cancer (GATC Cancer Study)
Adverse events due to medications are a common complication of the treatment of childhood cancer. This study is attempting to identify genetic risk factors that may be associated with adverse drug events. We have designed a case-control study to investigate all adverse events, with an initial focus on anthracycline-induced cardiomyopathy and cisplatin induced hearing loss.
Through a partnership with Drs Michael Hayden and Bruce Carleton, and a 2 year grant from the C17 Research Network, we have made this study available to 17 hospitals.

Grants

Michael Cuccione Childhood Cancer Research Program Brain Tumour Grant, start up funding - Project: “Outcomes in brain tumors treated with a chemotherapy only approach”

Honours & Awards

Outstanding Junior Resident (July 2001)

Outstanding Resident Researcher Award (June 2002)

Research Group Members

Vivek Gill, Research Assistant